The potential for mutant p53 to skew decisions between replication bypass, DNA resection, or fork restart mechanisms—all of which can, in turn, inadvertently boost cellular mutational burdens—has crucial implications for tumor development and drug resistance. The gene discussed is TP53; the disease is neoplasm.